| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 83.22 | 7.1% | 18.9% |
| Total Income | 83.22 | 7.1% | 18.9% |
| Expenditure | 36.88 | 1.6% | 26.1% |
| PBT | 48.79 | 11.1% | 120.2% |
| Net Profit | 37.41 | 8.9% | 73.9% |
| OPM | 55.69% | 2.38pp | 27.00pp |
| NPM | 44.96% | 0.75pp | 14.23pp |
| EPS | 0.29 | 11.5% | 81.3% |
Aurinia Pharmaceuticals Reports Q2 2026 Financial Results, Total Revenue Up 19% YoY
06 Aug 2026 · 6 Aug, 5:38 pm
Summary
Aurinia Pharmaceuticals reported strong financial results for the second quarter of 2026, with total revenue reaching $83.2 million, a 19% increase year-over-year. Net income saw a substantial rise of 74% to $37.4 million, and diluted earnings per share grew by 75% to $0.28. The company reiterated its full-year 2026 revenue guidance, projecting between $315 million and $325 million, indicating continued growth expectations.
Key Highlights
- 1
Total revenue for the three months ended June 30, 2026, was $83.2 million, an increase of 19% compared to the same period in 2025.
- 2
Net product sales of LUPKYNIS reached $79.4 million for the three months ended June 30, 2026, up 19% year-over-year.
- 3
Net income for the three months ended June 30, 2026, was $37.4 million, a significant increase of 74% from $21.5 million in the prior year period.
- 4
Diluted earnings per share for the three months ended June 30, 2026, were $0.28, up 75% compared to $0.16 in the same period of 2025.
- 5
Cash flows from operating activities for the three months ended June 30, 2026, were $52.5 million, an increase of 19% year-over-year.
- 6
Aurinia reiterates its guidance for 2026 total revenue of $315 million to $325 million, representing an 11% to 15% increase compared to 2025.
Management Comments
Michael Hearne
The information in this Current Report on Form 8-K and the exhibit hereto are being furnished pursuant to this Item 2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. In addition, the information included in this Current Report on Form 8-K and the exhibit hereto that is furnished pursuant to this Item 2.02 shall not be incorporated by reference in any of Aurinia's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such filing.
Informational and educational content only. Not investment advice.